GlaxoSmithKline Shells Out $1.33 Million to Idaho in Third Settlement



Pharmaceutical giant GlaxoSmithKline has agreed to pay the State of Idaho $1.33 million following an investigation in which 38 states—including Idaho—alleged that Glaxo had made claims that its diabetes drug Avandia had cardiovascular benefits, which it did not.

GlaxoSmithKline admitted no wrongdoing but ultimately shelled out $90 million to make the allegations go away.

Additionally, GlaxoSmithKline promised not to make any false, misleading or deceptive claims about any diabetes drug, promote investigational drugs or misuse statistics or misrepresent the significance of clinical trials.

Today's settlement is the third settlement between the office of Idaho Attorney General Lawrence Wasden and GlaxoSmithKline